Q-omics provides the consensus-scored PTTG2 profile across patient tissues and cancer cell-line models. PTTG2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PTTG2 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, PTTG2 RNA expression shows 12,093 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, and LSCC as cancer lineages where PTTG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTTG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTTG2 survival associations across molecular data types. PTTG2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTTG2 RNA expression–survival associations across cancer types. High PTTG2 expression shows unfavorable associations in KICH and UVM, but favorable associations in BLCA, SKCM, COAD and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PTTG2 RNA expression.
This table summarizes PTTG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTTG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTTG2 shows lower tumor expression in BLCA, READ, THCA, LUSC and UCEC and higher tumor expression in KICH. The BLCA box plot shows higher PTTG2 RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with PTTG2 in patient tissues and cancer cell lines. In patient samples, PTTG2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTTG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
